AU2006326936A1 - Antibacterial agents - Google Patents

Description

WO 2007/070947 PCT/AU2006/001939 1 Antibacterial Agents Field of Invention 5 The present invention relates to novel carbohydrate compounds and method of inhibiting bacterial growth. Background Since the introduction of penicillin over fifty years ago, there has been continuous growth 10 in the number of antibiotics commercially available for treatment of bacterial infections. As a result, today there are about 350 drugs on the market used for the treatment of a wide range of bacterial infections. One of the problems of continued use of existing drugs is the ever increasing acquisition of resistance through mutation and exchange of genes (Ritter et al Carbohydrate-Based Drug Discovery (2003), 899-932). Often patients with 15 bacterial infections cannot be treated adequately with the existing drugs, as many bacteria have developed multi-drug resistance. There is a great medical need for new antibacterials that are effective against the various multi-drug resistant bacteria. The Applicant has identified a number of new classes of compounds (PCT A U03/00384; PCT/AU2003/001008)). Several compounds described in these applications have now 20 been shown to possess promising antimicrobial activity, including activity against MRSA (Methicillin-resistant Staphylococcus aureus) and VRE (vancomycin-resistant enterococci). In addition, several new chemotypes have been identified with potent antimicrobial activity. The applicant has. also discovered disaccharides that have antibacterial properties (PCT/AU2003/01377). None of the new drugs in the art contain 25 small molecules based on monosaccharide scaffolds as disclosed in these patents applications. WO 03/070715 discloses antimicrobial agents comprising glycofuranose compounds derived from hexose sugars which are different from the compounds of the present invention because the compounds of the present invention are either glycopyranose compounds of hexose sugars or glycofuranose compounds of pentose 30 sugars.

WO 2007/070947 PCT/AU2006/001939 2 Summary of the invention It is an object of the present invention to provide novel compounds and new uses of various related compounds. 5 The present invention, in one aspect, provides a method of inhibiting bacterial growth by contacting bacteria with an effective amount of at least one monosaccharide compound of formula (1): 10 O0 R1 R5 R4 R2 R3 n formula I Wherein, n is 0 or 1; the ring may be of any configuration and the anomeric center may be 15 of either the c or 13 configuration; R1 is selected from the group consisting of hydrogen; OZ; SZ; OPO 2 (OZ)Z;

SO

2 N(Z)Q; S(--O)N(Z)Q; N-Het wherein N and Het combine to form a heterocycle which may be further substituted with one or more U moieties; and -N(Z)Y wherein: 20 Y is selected from hydrogen, or the following, where G denotes the point of connection to the nitrogen atom in N(Y)Z; WO 2007/070947 PCT/AU2006/001939 3 O 0 o G S G W G "W SG SW O 0 0 S G PO W G NW G

NI

W OH I I Q 5 Q is selected from hydrogen or W; the groups W are independently selected from alkyl, alkenyl, alkynyl, heteroalkyl, aryl, heteroaryl, arylalkyl or heteroarylalkyl of 1 to 20 carbon atoms which is optionally substituted, branched and/or linear. Typical substituents include but are not limited to OH, NO, NO 2 , NH 2 , N 3 , halogen, CF 3 , CHF 2 , CH 2 F, nitrile, alkoxy, aryloxy, amidine, 10 guanidiniums, carboxylic acid, carboxylic acid ester, carboxylic acid amide, aryl, cycloalkyl, heteroalkyl, heteroaryl, aminoalkyl, aminodialkyl, aminotrialkyl, aminoacyl, carbonyl, substituted or unsubstituted imine, sulfate, sulfonamide, phosphate, phosphoramide, hydrazide, hydroxamate, hydroxamic acid; the term heteroalkyl includes alkyl groups which incorporate one or more heteroatoms within the alkyl chain; 15 each occurrence of Z is independently selected from the group consisting of: hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, acyl, arylacyl, heteroarylacyl, aryl, heteroaryl, arylalkyl or heteroarylalkyl of 1 to 20 carbon atoms which is optionally substituted, branched and/or linear. Typical substituents include but are not limited to 20 OH, NO, NO 2 , NH 2 , N 3 , halogen, CF 3 , CHF 2 , CH 2 F, nitrile, alkoxy, aryloxy, amidine, guanidiniums, carboxylic acid, carboxylic acid ester, carboxylic acid amide, aryl, cycloalkyl, heteroalkyl, heteroaryl, aminoalkyl, aminodialkyl, aminotrialkyl, aminoacyl, carbonyl, substituted or unsubstituted imine, sulfate, sulfonamide, phosphate, WO 2007/070947 PCT/AU2006/001939 4 phosphoramide, hydrazide, hydroxamate, hydroxamic acid; the term heteroalkyl includes alkyl groups which incorporate one or more heteroatoms within the alkyl chain; or wherein each occurrence of U is independently selected from the group consisting of: 5 OH, NO, NO 2 , NH 2 , N 3 , halogen, CF 3 , CHF 2 , CH 2 F, nitrile, alkoxy, aryloxy, amidine, guanidinium, carboxylic acid, carboxylic acid ester, carboxylic acid amide, aryl, cycloalkyl, heteroalkyl, heteroaryl, aminoalkyl, aminodialkyl, aminotrialkyl, aminoacyl, carbonyl, substituted or unsubstituted imine, sulfate, sulfonamide, phosphate, phosphoramide, hydrazide, hydroxamate, hydroxamic acid; heteroaryloxy, aminoaryl, 10 aminoheteroaryl, thioalkyl, thioaryl, thioheteroaryl, alkyl, alkenyl, alkynyl, acyl, arylacyl, heteroarylacyl; of 1 to 20 carbon atoms which is optionally substituted, branched and/or linear. The groups R2, R3, R4 and R5 are independently selected from OZ or N-Het wherein N 15 and Het combine to form a heterocycle which may be further substituted with U groups; or N(Z)Y or OP0 2 (OZ)Z, wherein the groups Z and Y are as defined above. It is understood that the rules of molecular stoichiometry will be upheld by the default addition of hydrogen atoms as required. 20 In a preferred embodiment, the invention relates the method wherein the compound is selected from the group consisting of the gluco- or galacto- or allo- configuration. In a preferred embodiment the invention relates to said method wherein at least one of 25 R1-R5 is N-Het. In a preferred embodiment the invention relates to a method wherein the heterocycle is a monocyclic or bicyclic ring of 4 to 10 membered ring structure.

WO 2007/070947 PCT/AU2006/001939 5 In a preferred embodiment the invention relates to a method wherein the heterocyclic ring is selected from the group consisting of triazoles, benzimidazoles, benzimidazolothione, benzimidazolone, imidazole, hydanthione, thiohydanthione and purine. 5 In a preferred embodiment the invention relates to a method wherein any one of R2 and R4 is N-Het, wherein the heterocycle is a monocyclic or bicyclic ring of 4 to 10 membered ring structure. In another aspect, the inventionprovides a compound of formula (1) wherein wherein any 10 one of R1-R5 is N-Het. In a preferred embodiment, the invention relates to a compound of formula (1) wherein the heterocycle is a monocyclic or bicyclic ring of 4 to 10 membered ring structure. 15 In a preferred embodiment the invention relates to the compound of formula (1) wherein any one of R2 and R4 is N-Het, wherein the heterocycle is a monocyclic or bicyclic ring of 4 to 10 membered ring structure. In a preferred embodiment, the invention relates the compound of formula (1) wherein 20 the compound is selected from the group consisting of the gluco- or galacto- or allo configuration. In a preferred embodiment the invention relates to the compound of formula (1) wherein the heterocyclic ring is selected from the group consisting of triazoles, benzimidazoles, 25 benzimidazolothione, benzimidazolone, imidazole, hydanthione, thiohydanthione and purine. In a preferred embodiment, the heterocyclic ring may be further substituted with U groups; wherein each occurrence of U is independently selected from the group 30 consisting of: OH, NO, NO 2 , NH 2 , N 3 , halogen, CF 3 , CHF 2 , CH 2 F, nitrile, alkoxy, aryloxy, amidine, guanidinium, carboxylic acid, carboxylic acid ester, carboxylic acid WO 2007/070947 PCT/AU2006/001939 6 amide, aryl, cycloalkyl, heteroalkyl, heteroaryl, aminoalkyl, aminodialkyl, aminotrialkyl, aminoacyl, carbonyl, substituted or unsubstituted imine, sulfate, sulfonamide, phosphate, phosphoramide, hydrazide, hydroxamate, hydroxamic acid; heteroaryloxy, aminoaryl, aminoheteroaryl, thioalkyl, thioaryl, thioheteroaryl, alkyl, alkenyl, alkynyl, acyl, 5 arylacyl, heteroarylacyl; of 1 to 20 carbon atoms which is optionally substituted, branched and/or linear. In a preferred embodiment, the heterocyclic ring may be further substituted with U groups selected from the group consisting of substituted alkyl, aryl, carboxyl and amino. 10 In a preferred embodiment, the U group is selected from the group consisting of OH, NO,

NO

2 , NH 2 , N 3 , halogen, CF 3 , CHF 2 , CH 2 F, nitrile, alkoxy, aryloxy, amidine, guanidinium, carboxylic acid, carboxylic acid ester, carboxylic acid amide, aryl, cycloalkyl, heteroalkyl, heteroaryl, primary or secondary or tertiary amines, aminoacyl, 15 carbonyl and substituted or unsubstituted imine. The term primary, secondary and tertiary amines includes alkyl and aryl amines. In a preferred embodiment, each occurrence of Z is independently selected from the group consisting of: hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, acyl, arylacyl, 20 heteroarylacyl, aryl, heteroaryl, arylalkyl or heteroarylalkyl of 1 to 20 carbon atoms which is optionally substituted, branched and/or linear. In a preferred embodiment, the term "optionally substituted " or "optional substituents" include OH, NO, NO 2 , NH 2 , N 3 , halogen, CF 3 , CHF 2 , CH 2 F, nitrile, alkoxy, aryloxy, 25 amidine, guanidiniums, carboxylic acid, carboxylic acid ester, carboxylic acid amide, aryl, cycloalkyl, heteroalkyl, heteroaryl, aminoalkyl, aminodialkyl, aminotrialkyl, aminoacyl, carbonyl, substituted or unsubstituted imine, sulfate, sulfonamide, phosphate, phosphoramide, hydrazide, hydroxamate, hydroxamic acid; the term heteroalkyl includes alkyl groups which incorporate one or more heteroatoms within the alkyl chain. 30 In a preferred embodiment, the compound is selected from the group- consisting of: WO 2007/070947 PCT/AU2006/001939 7

CF

3

CF

3

CF

3 N N\ N LN OH )LN OH N H H H NH N---~O HA H HO H o HO HO / NH / NH O S NH NH

CF

3 CI CF 3 CI CF 3 5 In another aspect, the invention provides a compound of formula (1) wherein R1 is silyloxy and R2, R3, R4 and R5 are as defined above. Typical silyloxy groups include tertiary-butyldiphenylsilyloxy, teriary-butyldimethylsilyloxy and other similar alkyl and aryl silyloxy groups. 10 The term "halogen" denotes fluorine, chlorine, bromine or iodine, preferably fluorine, chlorine or bromine. The term "alkyl" used either alone or in compound words such as "optionally substituted 15 alkyl", "optionally substituted cycloalkyl", "arylalkyl" or "heteroarylalkyl", denotes straight chain, branched or cyclic alkyl, preferably C1-20 alkyl or cycloalkyl. Examples of straight chain and branched alkyl include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, amyl, isoamyl, sec-amyl, 1,2-dimethlylpropyl,1, .1 dimethylpropyl, hexyl, 4-methylpentyl, 1-methylpentyl, 2-methylpentyl, 3 20 methylpentyl, 1, 1-dimethylbutyl, 2,2-dimethylbutyl, 3,3-dimethylbutyl, 1, 2 dimethylbutyl, 1,3-dimethylbutyl, 1,2,2trimethylpropyl,1, 1,2-trimethylpropyl, heptyl, 5 methylbexyl, 1-methylhexyl, 2,2-dimethypentyl, 3,3 dimethylpentyl, 4,4-dimethylpentyl, 1,2-dimethylpentyl, 1,3-dimethylpentyl, 1,4-dimnethylpentyl, 1,2,3trimethylbutyl,1, 1,2 trimethylbutyl, 1,1,3-trimethylbutyl, octyl, 6-methylheptyl, 1-methylheptyl, 25 1,1,3,3tetramethylbutyl, nonyl,1-, 2-, 3-, 4-, 5-, 6-or 7methyloctyl,1-, 2-, 3-, 4-or 5- WO 2007/070947 PCT/AU2006/001939 8 ethylheptyl, 1-, 2-or 3propylhexyl, decyl,1-, 2-, 3-, 4-, 5-, 6-, 7- or 8-methylnonyl,1-, 2-, 3-, 4-, 5-or 6-ethyloctyl, 1-, 2-, 3or 4-propylheptyl, undecyll-, 2-, 3-, 4-, 5-, 6-, 7-, 8or 9 methyldecyl,1-, 2-, 3-, 4-, 5-, 6-or 7-ethylnonyl,l-, 2-, 3-, 4-or 5-propyloctyl,1-, 2-or 3 butylheptyl,1-pentylhexyl, dodecyl,1-, 2-, 3-, 4-, 5-, 6-, 7-, 8-, 9- or 10-methylundecyl,1-, 5 2-, 3-, 4-, 5-, 6-, 7-or 8- ethyldecyl,1-, 2-, 3-, 4-, 5-or 6-propylnonyl, 1-, 2-, 3- or 4 butyloctyl, 1-2 pentylheptyl and the like. Examples of cyclic alkyl include mono-or polycyclic alkyl groups such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl and the like. 10 The term "alkylene" used either alone or in compound words such as "optionally substituted alkylene" denotes the same groups as "alkyl" defined above except that an additional hydrogen has been removed to form a divalent radical. It will be understood that the optional substituent may be attached to or form part of the alkylene chain. 15 The term "alkenyl" used either alone or in compound words such as "optionally substituted alkenyl" denotes groups formed from straight chain, branched or cyclic alkenes including ethylenically mono-, di-or polyunsaturated alkyl or cycloalkyl groups as defined above, preferably C2-6 alkenyl. Examples of alkenyl include vinyl, allyl,1 methylvinyl, butenyl, iso-butenyl, 3-methyl-2butenyl, 1-pentenyl, cyclopentenyl, 1 20 methyl-cyclopentenyl, 1-hexenyl, 3-hexenyl, cyclohexenyl, 1l-heptenyl, 3-heptenyl, 1 octenyl, cyclooctenyl, 1-nonenyl, 2-nonenyl, 3-nonenyl, 1-decenyl, 3-decenyl, 1,3 butadienyl, 1,4-pentadienyl, 1,3 cyclopentadienyl, 1,3-hexadienyl, 1,4-hexadienyl, 1,3cyclohexadienyl, 1,4-cyclohexadienyl, 1,3-cycloheptadienyl, 1,3,5-cycloheptatrienyl and 1,3,5,7-cyclooctatetraenyl. 25 The term "alkynyl" used either alone or in compound words, such as "optionally substituted alkynyl" denotes groups formed from straight chain, branched, or mono-or poly-or cyclic alkynes, preferably C 2-6 alkynyl. 30 Examples of alkynyl include ethynyl,l-propynyl, 1-and 2butynyl, 2 -methyl-2-propynyl, 2-pentynyl, 3-pentynyl, 4pentynyl, 2-hexynyl, 3-hexylnyl, 4-hexynyl, 5-hexynyl, 10- WO 2007/070947 PCT/AU2006/001939 9 undecynyl,4-ethyl-l-octyn-3-yl, 7-dodecynyl, 9-dodecynyl, 10-dodecynyl,3-methyl-1 dodecyn-3-yl, 2-tridecynyl, 11tridecynyl, 3-tetradecynyl, 7-hexadecynyl, 3-octadecynyl and the like. 5 The term "alkoxy" used either alone or in compound words such as "optionally substituted alkoxy" denotes straight chain or branched alkoxy, .preferably C1-7 alkoxy. Examples of alkoxy include methoxy, ethoxy, npropyloxy, isopropyloxy and the different butoxy isomers. 10 The term "aryloxy" used either alone or in compound words such as "optionally substituted aryloxy" denotes aromatic, heteroaromatic, arylalkoxy or heteroaryl alkoxy, preferably C6-13 aryloxy. Examples of aryloxy include phenoxy, benzyloxy,1 napthyloxy, and 2-napthyloxy. 15 The term "acyl" used either alone or in compound words such as "optionally substituted acy I "or "heteroarylacyl" denotes carbamoyl, aliphatic acyl group and acyl group containing an aromatic ring, which is referred to as aromatic acyl or a heterocyclic ring which is referred to as heterocyclic acyl. Examples of acyl include carbamoyl; straight chain or branched alkanoyl such as formyl, acetyl, propanoyl, butanoyl, 2 20 methylpropanoyl, pentanoyl, 2,2-dimethylpropanoyl, hexanoyl, heptanoyl, octanoyl, nonanoyl, decanoyl, undecanoyl, dodecanoyl, tridecanoyl, tetradecanoyl, pentadecanoyl, hexadecanoyl, heptadecanoyl, octadecanoyl, nonadecanoyl, and icosanoyl; alkoxycarbonyl such as methoxycarbonyl, ethoxycarbonyl, t butoxycarbonyl, t pentyloxycarbonyl and heptyloxycarbonyl; cycloalkylcarbonyl such as 25 cyclopropylcarbonyl cyclobutylcarbonyl, cyclopentylcarbonyl and cyclohexylcarbonyl; alkylsulfonyl such as methylsulfonyl and ethylsulfonyl; alkoxysulfonyl such as methoxysulfonyl and ethoxysulfonyl; aroyl such as benzoyl, toluoyl and naphthoyl; aralkanoyl such as phenylalkanoyl (e. g. phenylacetyl, phenylpropanoyl, phenylbutanoyl, phenylisobutyl, phenylpentanoyl and phenylhexaioyl) and naphthylalkanoyl (e. g. 30 naphthylacetyl, naphthlpropanoyl and naphthylbutanoyl); aralkenoyl such as phenylalkenoyl (e. g. phenylpropenoyl, phenylbutenoyl, phenylmethacrylyl, WO 2007/070947 PCT/AU2006/001939 10 phenylpentenoyl and phenylhexenoyl and naphthylalkenoyl (e. g. naphthylpropenoyl, naphthylbutenoyl and naphthylpentenoyl); aralkoxycarbonyl such as phenylalkoxycarbonyl (e. g. benzyloxycarbonyl); aryloxycarbonyl such as phenoxycarbonyl and naphthyloxycarbonyl; aryloxyalkanoyl such as phenoxyacetyl and 5 phenoxypropionyl; arylcarbamoyl such as phenylcarbamoyl; arylthiocarbamoyl such. as phenylthiocarbamoyl; arylglyoxyloyl such as phenylglyoxyloyl and naphthylglyoxyloyl; arylsulfonyl such as phenylsulfonyl and naphthylsulfonyl; heterocycliccarbonyl; heterocyclicalkanoyl such as thienylacetyl, thienylpropanoyl, thienylbutanoyl, thienylpentanoyl, thienylhexanoyl, thiazolylacetyl, thiadiazolylacetyl and 10 tetrazolylacetyl; heterocyclicalkenoyl such as heterocyclicpropenoyl, heterocyclicbutenoyl, heterocyclicpentenoyl and heterocyclichexenoyl; and heterocyclicglyoxyloyl such as thiazolylglyoxyloyl and thienyglyoxyloyl. The term "aryl" used either alone or in compound words such as "optionally substituted 15 aryl", "arylalkyl" or "heteroaryl" denotes single, polynuclear, conjugated and fused residues of aromatic hydrocarbons or aromatic heterocyclic ring systems. Examples of aryl include phenyl, biphenyl, terphenyl, quateirphenyl, phenoxyphenyl, naphthyl, tetrahydronaphthyl, anthracenyl, dihydroanthracenyl, benzanthracenyl, dibenzanthracenyl, phenanthrenyl, fluorenyl, pyrenyl, indenyl, azulenyl, chrysenyl, 20 pyridyl, 4-phenylpyridyl, 3-phenylpyridyl, thienyl, furyl, pyrryl, pyrrolyl, furanyl, imadazolyl, pyrrolydinyl, pyridinyl, piperidinyl, indolyl, pyridazinyl, pyrazolyl, pyrazinyl, thiazolyl, pyrimidinyl, quinolinyl, isoquinolinyl, benzofuranyl, benzothienyl, purinyl, quinazolinyl, phenazinyl, acridinyl, benzoxazolyl, benzothiazolyl and the like. Preferably, the aromatic heterocyclic ring system contains 1 to 4 heteroatoms 25 independently selected from N, O and S and containing up to 9 carbon atoms in the ring. The term "heterocycle" used either alone or in compound words as "optionally substituted heterocycle" denotes monocyclic or polycyclic heterocyclyl groups containing at least one heteroatom atom selected from nitrogen, sulphur and oxygen. Suitable heterocyclyl 30 groups include N-containing heterocyclic groups, such as, unsaturated 3 to 6 membered heteromonocyclic groups containing 1 to 4 nitrogen atoms, for example, pyrrolyl, WO 2007/070947 PCT/AU2006/001939 11 pyrrolinyl, imidazolyl, pyrazolyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazolyl or tetrazolyl; saturated to 3 to 6-membered heteromonocyclic groups containing 1 to 4 nitrogen atoms, such as, pyrrolidinyl, imidazolidinyl, piperidin or piperazinyl ; unsaturated condensed heterocyclic groups containing 1 to 5 nitrogen atoms, such as, 5 indolyl, isoindolyl, indolizinyl, benzimidazoyl, quinolyl, isoquinolyl, indazolyl, benzotriazolyl or tetrazolopyridazinyl; unsaturated 3 to 6-membered heteromonocyclic group containing an oxygen atom, such as, pyranyl or furyl; unsaturated 3 to 6-membered heteromonocyclic group containing 1 to 2 sulphur atoms, such as, thienyl; unsaturated 3 to 6-membered heteromonocyclic group containing 1 to 2 oxygen atoms and 1 to 3 10 nitrogen atoms, such as, oxazolyl, isoxazolyl or oxadiazolyl; saturated 3 to 6-membered heteromonocyclic group containing 1 to 2 oxygen atoms and 1 to 3 nitrogen atoms, such as, morpholinyl; unsaturated condensed heterocyclic group containing 1 to 2 oxygen atoms and 1 to 3 nitrogen atoms, such as, benzoxazolyl or benzoxadiazolyl; unsaturated 3 to 6-membered heteromonocyclic group containing 1 to 2 sulphur atoms and 1 to 3 15 nitrogen atoms, such as, thiazolyl or thiadiazolyl; saturated 3 to 6-membered heteromonocyclic group containing 1 to 2 sulphur atoms and 1 to 3 nitrogen atoms, such as thiazolidinyl; and unsaturated condensed heterocyclic group containing 1 to 2 sulphur atoms and 1 to 3 nitrogen atoms, such as, benzothiazolyl or benzothiadiazolyl. 20 In another form, the invention comprises a method of inhibiting bacterial growth in an animal or human comprising administering an effective amount of at least one monosaccharide compound of formula (1). In another aspect, the invention provides for a pharmaceutical composition comprising at 25 least one of the compounds described herein, or tautomers, esters, solvates, or pharmaceutically acceptable salts thereof, and a pharmaceutically acceptable carrier. The bacterial may be Gram-positive or Gram-negative bacteria. The bacteria may comprise an E-coli bacteria, a Staphylococci Bacteria such as Staphylococcus aureus, or 30 other bacteria such as Micrococcus luteus (ATCC272), Staphylococcus aureus (ATCC29213), Staphylococcus aureus (ATCC43300) MRSA, Enterococcus faecalis WO 2007/070947 PCT/AU2006/001939 12 (ATCC29212), Enterococcus faecalis (ATCC51299) Vancomycin resistant and Streptococcus pyogenes (ATCC8668). The method may comprise administering an effective amount of a compound of the first 5 aspect, to a subject in need of such treatment. The subject may be a human, or may be a domestic, companion or zoo animal. In another form, the invention may reside in an antibacterial composition comprising at least one compound as described above. The composition may comprise a pharmaceutical 10 composition. The compounds of the invention may be mixed with a pharmaceutical acceptable carrier, adjuvant, or vehicle, which may comprise a-toxic carrier, adjuvant, or vehicle that may be administered to a patient, together with a compound of this invention, and which does not 15 destroy the pharmacological activity thereof. The pharmaceutical derivative may comprise a salt, ester, salt of an ester or other derivative of a compound of this invention which, upon administration to a recipient, is capable of providing, either directly or indirectly, a compound of this invention, although 20 no limitation is meant thereby. Compounds of the invention may be administered orally such as by means of a tabled, powder, liquid, emulsion, dispersion and the like; by inhalation; topically such as by means of a cream, ointment, salve etc; and as a suppository, although no limitation is 25 meant thereby. The compounds of the invention may be administered together with one or more drugs, including antibacterial agents such as antibiotics, for the treatment of bacterial infections. 30 In another aspect, the invention provides a compound of formula (1) when used for the treatment of a disease.

WO 2007/070947 PCT/AU2006/001939 13 In another aspect, the invention provides a pharmaceutical composition comprising a compound of formula (1) when used for the treatment of a disease. 5 Methods and pharmaceutical carriers for preparation of pharmaceutical compositions are well known in the art, as set out in textbooks such as Remington's Pharmaceutical Sciences, 19th Edition, Mack Publishing Company, Easton, Pennsylvania, USA. It will be clearly understood that, if a prior art publication is referred to herein, this 10 reference does not constitute an admission that the publication forms part of the common general knowledge in the art in Australia or in any other country. Detailed Description of the Invention 15 Various non-limiting embodiments of the invention will be described with reference to the following examples. Where appropriate, the following abbreviations are used. Ac Acetyl DTPM 5-Acyl-1,3-dimethylbarbiturate DIPEA 20 Ph Phenyl TBDMS t-Butyldimethylsilyl TBDPS t-Butyldiphenylsilyl Bn benzyl Bz benzoyl 25 Me methyl DCE 1,2-diclhloroethane DCM dichloromnethane, methylene chloride Tf trifluoromethanesulfonyl Ts 4-methylphenylsulfonyl, p-toluenesulfonyl 30 DMF N,N-dimethylfonnrmamide DMAP N,N-dimethylaminopyridine WO 2007/070947 PCT/AU2006/001939 14 0.0-DMT .0-dimethoxytoluene, benzaldehyde dimethyl acetal DMSO dimethylsulfoxide DTT dithiothreitol DMTST Dimethyl(methylthio)sulphoniumtrifluoro- methanesulphonate 5 TBAF tetra-n-butylammonium fluoride Generally applicable synthetic procedures A) Fmoc Removal 10 The resins were washed with dry DMF then treated with 1.5 mL of a solution of 20% v/v piperidine in DMF . The resins were shaken for lh and then drained and washed with DMF. The procedure was then repeated with the resins being finally washed with DMF (x3), MeOH (x3) and DCM (x3). 15 B) Cleavage from Resin (and Removal of any Boc Groups on Side Chains) Each resin was treated with a solution of 10 % TFA, 20 % Et 3 SiH in dry DCM (1.5 ml) for 3 h, drained into a test tube and washed with DCM (2.0 ml), The samples were concentrated in vacuo on the RVC. Each cleaved product was treated with a solution of saturated ammonia in methanol (1.0 20 ml) and left at room temperature for 2 h. The samples were -again concentrated in vacuo on the RVC. C) Acylation Acylating mixtures were prepared by dissolving the requisite carboxylic acid (0.5mM) in 25 anhydrous DMF (0.5 mL) and treating this solution first with HBTU (0.5mM) followed by DIPEA (0.5 mM). Following mixing, each solution was allowed to stand for 10 min. prior to addition of the resin bound substrate. The reaction mixture was shaken at room temperature overnight, filtered and washed with DMF (x 3), MeOH (x 1), DMF (x 3), MeOH (x 1) and DCM (x 3). 30 WO 2007/070947 PCT/AU2006/001939 15 D) Reduction of Azide Equal volumes of a solution of 1,4-Dithio-DL-threitol (DTT, 0.2 M in DMF) and lithium tert-butoxide (0.2 M in DMF) were added to the resin bound substrate and the reaction mixture shaken at room temperature for 6 h. The resin was drained, washed with dry 5 DMF (x 3), dry THF (x 3), dry MeOH (x 3), dry DCM (x 3) and dried in vacuo. Synthetic Schemes Synthetic schemes are given for two of the libraries synthesised as being representative of the general approach taken during monosaccharide synthesis. This is not exhaustive and 10 variations on these approaches were used. TG 24 N Oii ,, or Ro 2= C

R

3 0 R 3 O mror R 3 O N NHDTPM NH 2 NH H

R

2 = - - CF 3 3 H02

R

3 = 0 2 N 9 R4NH 0 v, v

H

2 N 0

R

3 0 O o, ii R 3 0 0 NH NH R2 R )11o9 )1o1 FmocHN NH 0 H 2 N NH 0 O x O H NH

NO

2 R2 NO 2

R

WO 2007/070947 PCT/AU2006/001939 16 R4 R4 NH 0 NH0 R 0 R4 R0 xi R3N 0 NH NH Conditions: i) a) LiOtBu (0.5 M) in DMF, 10 min. b) 1-Fluoro-2-nitrobenzene (0.5 M) in 12 2

N

2 DMF, 20 min., 3 cycles ii) 5 % NH2 2.H20 in DMF, 1 h iii) 4-Chloro-3 5 (trifluoromethyl)phenyl isocyanate (0.15 M) in DMF, o/n iv) 4 (Trifluoromethyl)benzenesulfonyl chloride (0.1 M) and DIPEA (0.2 M) in DCM, o/n v) LiOtBu (0.2 M) and DTT (0.2 M) in DMF, 6 h vi) Aldehyde (0.2 M), NaCNBH3 (0.175 NM) in THF / MeOH / AcOH (2:2:1), o/n vii) Biphenyl-4-sulfonyl chloride (67.2 mM) 3 in DMF, o/n xi) 10 % TFA, 20 %Et3SiH in DCM.O NH NH ' 2 2 R Conditions: i) a) LiO t Bu (0. 5 M) in DMvF, 10 min. b) 1 -Fluoro-2-nitrobenzene (0. 5 M) in DMF, 20 min., 3 cycles ii) 5 % N11 2 N11 2

.H

2 0 in DMF, 1 h iii) 4-Chloro-3 5 (trifiuoromethyl)phenyl isocyanate (0.15 M) in DMF, o/n iv) 4 (Trifluoromethyl)benzenesulfonyl chloride (0.1 M) and DIPLA (0.2 M) in DCM, o/n v) LiO t Bu (0.2 M) and DTT (0.2 M) in DMF, 6 h vi) Aldehyde (0.2 M), NaCNBH 3 (0.175 M) in THF / MeGH / AcOH (2:2:1), 0/n vii) Biphenyl-4-sulfonyl chloride (67.2 mM) and DJPEA (0.1348 M) in DCM, o/n viii) Acid (9.25 M), HBTU (0.25 M) and DIPBA 10 (0.5 M) in DMF, o/n ix) 20 % piperidine in DMF, 1 h, 2 cycles x) SnC1 2 .2H 2 0 (2.0 M) in DMF, o/n xi) 10 % TFA, 20 %EtjSiH in DCM.

WO 2007/070947 PCT/AU2006/001939 17 TG26

CF

3 N 0 NO N 0 H N 0 0 2 N R1 ) 0 O O3 r- 0 (iv) NH HO HO- HO- HO NHDTPM NH 2 NH NH HO X2 X2 NH

R

2

R

2

X

2

F

3 C F 3 C

R

2 NF R. (x) NF RF( O O N O H Acylate F 3 C (V,) HN

H

O HN HO 0 (vii)

R

4 NH R4 ,NH N X2 X2 N O 2 C R2 2 HO O 1. CNBr CF 3

F

3 C F3 NH (vi) 7Alkylate RCH 2 Br X2 R1 R1 (x) ' N R1( (viii) R2 H2 N R9 ON () N R Iminobenzimidazole N RNH R N NH O NH HO NHI R4 NH R IX 2 R X2 2 CF3 2 2. RNCS

P

2 2 S Common intermediate

CF

3 (iX) "- R 1 - N 0 N NH N 0 R 4 N HO o R NH ,NH SHO X2 NH

R

2

X

2 R2 Conditions: (i) 5 % NH 2

NH

2

.H

2 0zO in DMF, 1.5 h (ii) 4-chloro-3-trifluoromethyl 5 isocyanate in DMF at room temperature overnight or 4-trifluoromethyl sulphonyl chloride (2eq) and DIPEA (4eq) in DCM overnight (iii) DTT (0.2M) and Li-t-BuO (0.2M) in DMF at room temperature overnight (iv) 4-fluoro-3-nitro-benzotrifluoride (5eq) or 3-chloro-4-fluoro-5-nitro-benzotrifluoride (3.5eq) and DIPEA (0.25M) in DMF at 50 0 C overnight (v) SnCl 2 .2H 2 0 (2.0M) in DMF overnight (vi) CNBr (1.0M) in DCM 10 (vii) Amino acid (3eq) and DIPEA (4eq) in DMF with HBTU solution (3eq) and shake overnight (viii) ArCH 2 Br (5eq, 0.4M) and DIPEA (10eq, 0.8M) in DMF at room temperature overnight (ix) Isothiocyanate (10eq) in DMF for 4h then drain and add DIC WO 2007/070947 PCT/AU2006/001939 18 in DMF and shake overnight (x) 10%TFA/20% Et 3 Si/70% DCM for 3h and treat dried product with saturated NH 3 in methanol solution for 2h. TG27

N

3 0 N 0

N

3 0 HO HO HO NHDTPM

NH

2 NH R

NO

2 R =H or Cl

CF

3 (v) (iv)iii) 0 0#

R

4 NH 0R 4 NH1 0 7 O( NH 0 HOR HO NH HO-N NH NH

R

2

NH

2

R

2

NO

2

R

2

NO

2

CF

3

CF

3

CF

3 Remove 2nd subset compounds Remove 1st subset of compounds O

R

4 NH 0 X = H for benzimidazole O OH for benzimidazolone Cyclise (vi) HO X SH for thiobenzimidazole Cleave (vii) N\ NH 2 for iminobenzimidazole NH 3 /MeOH (viii) R2 N

CF

3 5 Conditions: (i) 5 % NH 2

NH

2

.H

2 0 in DMF, 1.5 h (ii) 4-fluoro-3-nitro-benzotrifluoride or 3-chloro-4-fluoro-5-nitro-benzotrifluoride (0.25M) and DIPEA (0.25M) in DMF at 50'C overnight (iii) DTT (1.2M) and triethylamine (2.7M) in DMF at room temperature WO 2007/070947 PCT/AU2006/001939 19 overnight (iv) Amino acid (3eq) and DIPEA (4eq) in DMF with HBTU solution (3eq) and shake overnight (v) SnCl 2 .2H 2 0 (2.15M) in DMF overnight (vi) p-toluene sulfonic acid monohydrate in trimethylorthoformate (for benzimidazole), 1,1-carbonyldiimidazole (0.5M) in DCM (for benzimidazolone), 1,1-thiocarbonyldiimidazole (0.5M) in THF (for 5 thiobenzimidazole), CNBr (0.5M) in DCM (for iminobenzimidazole) (vii) 10%TFA/20% Et 3 Si/70% DCM for 3h (viii) Saturated NH 3 in methanol solution for 2h Experimental 10 General resin preparation common to each library Preparation of TCA resin To Wang resin (20 g, loading: 0.9 mmol/g, 18.0 mmol, dried over P 2 0 5 overnight) was added dry DCM (200 ml) and dry trichloroactonitrile (0.32 mol, 17.7 equiv.). The resin 15 suspension was cooled in an ice water bath and gently stirred for 15 min. DBU (13.4 mmol, 0.74 equiv.) was then added dropwise over 15 min. The resulting suspension was then gently stirred at 0 oC with occasional shaking for 1 h to give a dark brown suspension. The resin was then filtered in the glove box and washed with dry DMF (x 3), dry THF (x 3) and dry DCM (x 3). The resin was then dried on the high vac over KOH 20 overnight. Loading of TG Building Block onto TCA resin TCA resin (19.6 g, 15.6 mmol) was washed in the glove box with dry THF (x4). A solution of the appropriate building block (46.9 mmol, 3 equiv.) in dry DCM (75 ml) was 25 added to the resin, which was shaken for 3 min. BF 3 .OEt 2 (11.0 rmmol, 0.7 equiv.) was then added and the resin was shaken, for a further 10 min. The resin was drained and washed with dry DCM (x5). The combined filtrate was washed with sat NaHCO 3 (500 mnl), dried (MgSO 4 ) and the solvent was removed in vacuo to give the recovered building block. 30 The resin was washed further with dry THF (x4) and dry DCM (x4) and dried in vacuo overnight.

WO 2007/070947 PCT/AU2006/001939 20 Removal of para-Chlorobenzoate Group at 3 Position The resin bound substrate (22.2 g) was treated with a solution of NaOMe (30 mM) in dry THF (310 ml) and dry MeOH (62 ml). The resin was shaken overnight, filtered in the 5 glove box and washed with dry THF (x3), dry THF / acetic acid / dry MeOH (8:1:1, x5), dry THF (x3) and dry DCM (x3). The resin was dried in vacuo overnight. Library production 10 TG 23 Note: Resin with an SMe group at the anomeric position, as well as hydrogen, was used for this library. Alkylation at 3 Position with Methyl Iodide 15 The resin bound substrate was washed in the glove box with dry DMF (x3). A solution of lithium tert-butoxide in dry DMF (0.25 M) was added and the resin was shaken for 10 min. and drained. A solution of methyl iodide in dry DMF (0.25 M) was added and the resin was shaken for 20 min. The resin was then filtered and washed with dry DMF (x3). This cycle was performed an additional two times. The resin was finally washed in the 20 glove box with dry DMF (x3), dry THF / dry MeOH / acetic acid (8:1:1, x5), dry THF (x3), dry MeOH (x3) and dry DCM (x3). The resin was then dried on the high vac overnight. Urea Formation 25 The resin bound substrate was treated with a solution of DIPEA in dry DMF (0.36 M) and shaken at room temperature for 30 min. The resin was drained, washed with dry DMF (x 3) and treated with a solution of the isocyanate in dry DMF (0.15 M). The resin was shaken at room temperature overnight, drained and washed with DMF (x 3) and DCM (x 3). 30 WO 2007/070947 PCT/AU2006/001939 21 Sulfonamide Formation The resin bound substrate was treated with a solution the sulfonyl chloride (0.1 M) and DIPEA (0.2 M) in dry DCM and shaken at room temperature for 2." The resin was drained, washed with dry DCM (x 3), MeOH (x 3) and DCM (x 3). 5 TG24 Fluoride Displacement at 3 Position The resin bound substrate was washed in the glove box with dry DMF (x3). A solution of 10 lithium tert-butoxide in dry DMF (0.5 M) was added and the resin was shaken for 10 min. and drained. A solution of 1-fluoro-2-nitrobenzene in dry DMF (0.5 M) was added and the resin was shaken for 20 min. The resin was then filtered and washed with dry DMF (x3). This cycle was repeated twice. The resin was washed in the glove box with dry DMF (x3), dry THF / dry MeOH / acetic acid (8:1:1, x3), dry THF (x3), dry MeOH 15 (x3) and dry DCM (x3). The resin was then dried on the high vac overnight. Removal of DTPM Group at 2 Position The resin bound substrate was treated with a solution of 5 % hydrazine hydrate in DMF and shaken at room temperature for 1 h. The resin was drained, washed with DMF (x5) 20 and DCM (x3) and dried in vacuo. Urea Formation at 2 Position The resin bound substrate was washed in the glove box with dry DMF (x3). A solution of 4-chloro-3-(trifluoromethyl)phenyl isocyanate in dry DMF (0.15 M, 1.9 equiv.) was 25 added and the resin was shaken at room temperature overnight. The resin was filtered in the glove box, washed with dry DMF (x3) and dry DCM (x3) and dried in vacuo. Compounds with a free hydroxyl at the 3-position were subsequently treated in the following manner: the resin was then swollen in dry THF and treated with a solution of NaOMe in dry MeOH (0.3 M). The resin was heated at 70 'C and under nitrogen for 4 h, 30 allowed to cool, transferred into a solid phase vessel with dry THF and washed with dry WO 2007/070947 PCT/AU2006/001939 22 THF (x3), dry MeOH (x3) and dry DCM (x3). The resin was then dried on the high vac overnight. Sulfonamide Formation at 2 Position 5 The resin bound substrate was treated in the glove box with a solution of 4 (trifluoromethyl)-benzenesulfonyl chloride (0.11 M, 2 eq) and DIPEA (0.22 M, 4 eq) in dry DCM. The resin was shaken at room temperature overnight, filtered, washed in the glove box with dry DCM (x3), dry MeOH (x3) and dry DCM (x3) and dried in vacuo. 10 Reductive Amination at 4 Position A solution of aldehyde (0.2 M) and sodium cyanoborohydride (0.175 M) in dry THF / dry MeOH / acetic acid (2:2:1) was added to each resin bound substrate. The resins were shaken at room temperature overnight, filtered and washed with THF / MeOH (1:3, x 3), DMF / MeOH (1:3, x 3), DCM / MeOH (1:3, x 3) and DCM (x 3). 15 Sulfonamide Formation at 4 Position To each resin bound substrate was added a solution of biphenyl-4-sulfonyl chloride (76.2 mM) and DIPEA (0.135 M) in dry DCM. The resins were shaken at room temperature overnight, filtered and washed with DCM (x 3), MeOH (x 3) and DCM (x 3). 20 Reduction of Aromatic Nitro Group with Tin Chloride Each resin bound substrate was washed with DMF (x 2), then treated with a solution of SnCl 2 .2H 2 0 in DMF (2.0 M) and shaken at room temperature overnight. The resins were filtered and washed with DMF (x 3), DMF / MeOH (1:1, x 3), DMF (x 3), DMF / MeOH 25 (1:1, x 3) and DCM (x 3). TG25 Fluoride Displacement at 3 Position 30 The resin bound substrate was washed in the glove box with dry DMF (x3). A solution of lithium tert-butoxide in dry DMF (0.5 M) was added and the resin was shaken for 10 WO 2007/070947 PCT/AU2006/001939 23 min. and drained. A solution of 1-fluoro-2-nitrobenzene in dry DMF-(0.5 M) was added and the resin was shaken for 20 min. The resin was then filtered and washed with dry DMF (x3). This cycle was performed an addition two times. The resin was finally washed in the glove box with dry DMF (x3), dry THF / dry MeOH / acetic acid (8:1:1, x5), dry 5 THF (x3), dry MeOH (x3) and dry DCM (x3). The resin was then dried on the high vac overnight. Removal of DTPM Group at 2 Position The resin bound substrate was treated with a solution of 5 % hydrazine hydrate in DMF 10 and shaken at room temperature for 1 h. The resin was drained, washed with DMF (x5) and DCM (x3) and dried in vacuo. Urea Formation at 2 Position The resin bound substrate was washed in the glove box with dry DMF (x3). A solution of 15 4-chloro-3-(trifluoromethyl)phenyl isocyanate in dry DMF (0.15 M, 1.9 equiv.) was added and the resin was shaken at room temperature overnight. The resin was filtered in the glove box, washed with dry DMF (x3) and dry DCM (x3) and dried in vacuo. Compounds with a free hydroxyl at the 3-position were subsequently treated in the following manner: the resin was then swollen in dry THF and treated with a solution of 20 NaOMe in dry MeOH (0.3 M). The resin was heated at 70 oC and under nitrogen for 4 h, allowed to cool, transferred into a solid phase vessel with dry THF and washed with dry THF (x3), dry MeOH (x3) and dry DCM (x3). The resin was then dried on the high vac overnight. 25 Sulfonamide Formation at 2 Position The resin bound substrate was treated in the glove box with a solution of 4 (trifluoromethyl)-benzenesulfonyl chloride (0.11 M, 2 eq) and DIPEA (0.22 M, 4 eq) in dry DCM. The resin was shaken at room temperature overnight, filtered, washed in the glove box with dry DCM (x3), dry MeOH (x3) and dry DCM (x3) and dried in vacuo. 30 WO 2007/070947 PCT/AU2006/001939 24 Triazole Formation from Alkynes at 4 Position To each resin bound substrate was added a solution of the alkyne in dry toluene (0.44 M,). The resins were heated in test tubes in a graphite bath at 100 oC overnight, allowed to cool, transferred into solid phase tubes in the Bohdan Block with toluene and washed 5 with toluene (x 3), THF (x 3) and DCM (x 3). The resins were dried in vacuo for 2 h. The reaction was repeated. Triazole Formation from -Ketoesters at 4 Position To each resin bound substrate was added a solution of the P3-ketoester in dry DMF (0.5 10 M) followed by a solution of NaOEt in EtOH (0.5 M). The resins were heated in test tubes in a graphite bath at 100 oC overnight, allowed to cool, transferred into solid phase tubes in the Bohdan Block with DMF and washed with DMF (x 3), DMF / MeOH (1:1, x 3), DMF (x 3), DMF /'MeOH (1:1, x 3) and DCM (x 3). The resins were dried in vacuo for 2 h. The reaction was repeated for the biphenyl derivatives. 15 Each resin was then swollen in THF and then treated with a solution of lithium hydroxide monohydrate in water (1.5 M). The resins were shaken on a Merrifield shaker (reactions were not successful when performed using the Bohdan block presumable due to insufficient mixing) at room temperature overnight, drained and washed with THF (x 3), 20 MeOH (x 3), THF (x 3), MeOH (x 3) and DCM (x 3). Triazole Formation from 4-Biphenylacetonitrile at 4 Position To the resin bound substrate was added a solution of 4-biphenylacetonitrile in dry DMF (0.5 M) followed by a solution of NaOEt in EtOH (0.5 M). The resin was heated in a test 25 tube in a graphite bath at 100 oC overnight, allowed to cool, transferred into solid phase tubes in the Bohdan Block with DMF and washed with DMF (x 3), DMF / MeOH (1:1, x 3), DMF (x 3), DMF / MeOH (1:1, x 3) and DCM (x 3). The resin was dried in vacuo for 2 h. 30 TG26 WO 2007/070947 PCT/AU2006/001939 25 DTPM removal The resin bound substrate was treated with a solution of 5 % hydrazine hydrate in DMF and shaken at room temperature for 1.5 h. The resin was drained, washed with DMF (x5) and DCM (x3) and dried in vacuo. 5 Urea formation The resin bound substrate was washed with dry DMF and then the 4-chloro-3 trifluoromethyl isocyanate in DMF added and the reaction shaken overnight. The resin was drained and washed with DMF, MeOH and DCM. 10 Compounds with a free hydroxyl at the 3-position were subsequently treated in the following manner: The resin bound substrate was shaken for 3h with a NaOMe solution (0.15M) made by dissolving 260mg of Na metal in MeOH (15mL) and mixing with THF (65mL). The resin was washed with THF (x3), MeOH (x3) and DCM (x3) and dried under vacuum. 15 Sulphonamide formation The resin bound substrate was washed with dry DCM (x3) and DIPEA (4eq, 0.3M) in DCM added. 4-Trifluoromethyl sulfonylchloride (2eq, 0.15M) was taken up in DCM and also added to the resin and shaken overnight. The resin was drained and washed with 20 DCM (x3), MeOH (x3) and DCM (x3). Fluoride displacement at the 4-position Resin bound substrates were treated with a solution of either 4-fluoro-3-nitro benzotrifluoride (5.40mmol, Seq) or 3-chloro-4-fluoro-5-nitro-benzotrifluoride 25 (3.75mmol, 3.Seq) and DIPEA (5.4mmol) in DMF (15mL) at 50 oC overnight without shaking. The resins were then transferred into fritted vessels and drained and washed with dry DMF (x 3), dry MeOH (x 3), dry DCM (x 3) and dried in vacuo. Tin (II) chloride nitro reduction 30 Each resin bound substrate was washed with DMF (x 2), then treated with a solution of SnC1 2 .2H 2 0 in DMF (2.0 M) and shaken at room temperature overnight. The resins were WO 2007/070947 PCT/AU2006/001939 26 drained and washed with DMF (x 3), DMF / MeOH (1:1, x 3), DMF (x 3), DMF / MeOH (1:1, x 3) and DCM (x 3). Cyclisation to the 4-iminobenzimidazole 5 Resin bound substrated was washed with anhydrous DCM then treated with cyanogen bromide (IM in DCM) overnight. After this time, the resins were then drained and washed with DCM (x3), MeOH (x3) and DCM (x3). Acylation of the iminobenzimidazole (anhydride/DIC method) 10 A solution was made up of each amino acid (1.6mmol) and DIC (0.125mL) in DMF (3.8mL). This was stirred for one hour and then one solution was added to each resin bound substrate and the reaction mixture was shaken overnight. The resins were drained and washed with DMF (x3), MeOH (x3) and DCM (x3). 15 The resin bound substrates were subsequently treated with a solution of sodium methoxide 0.1 M in THF/MeOH (5:1) overnight then drained and washed with THF (x3), MeOH (x3), THF (x3) and DCM (x3). Alkylation of the iminobenzimidazole 20 Each resin bound substrate was treated with a solution containing a substituted aryl bromide (5eq, 0.4M) and DIPEA (10eq, 0.8M) in DMF. The solutions were shaken overnight. The resins were drained and washed with DMF (x3), MeOH (x3) and DCM (x3). 25 Cyclisation with the aromatic isothiocyanates Resin bound substrate was treated with a solution of an aromatic isothiocyanates (3.08mmol, 10eq) in DMF for 4h and then drained. Following this treatment, a solution of DIC (3.08mmol, 10eq) in DMF was added and the reaction mixturewas shaken overnight. The resins were then drained and washed with DMF (x3), MeOH (x3) and 30 DCM (x3).

WO 2007/070947 PCT/AU2006/001939 27 Cyclisation with decyl isothiocyanate The decyl isothiocyanate (6.16mmol, 20eq) and DIPEA (9.24mmol, 30eq) were taken up in DMF and added to each of the resin bound substrates. The resins were shaken overnight and then drained and washed with DMF (x3). A solution of DIC (20eq, 1.54M) 5 in DMF was added to each resin and the mixture shaken overnight. The resins were then drained and washed with DMF (x3), MeOH (x3) and DCM (x3). TG27 10 DTPM removal The resin bound substrate was treated with a solution of 5 % hydrazine hydrate in DMF and shaken at room temperature for 1.5 h. The resin was drained, washed with DMF (x5) and DCM (x3) and dried in vacuo. 15 Fluoride displacement at the 2-position Resin bound substrates were treated with a solution of either 4-fluoro-3-nitro benzotrifluoride (5.40mmol, Seq) or 3-chloro-4-fluoro-5-nitro-benzotrifluoride (3.75mmol, 3.5eq) and DIPEA (5.4mmol) in DMF (15mL) at 50 oC overnight without shaking. The resins were then transferred into fritted vessels and drained and washed with 20 dry DMF (x 3), dry MeOH (x 3), dry DCM (x 3) and dried in vacuo. Tin (II) chloride reduction Resin bound substrate was washed with DMF (x 2), then treated with a solution of SnCl 2 .2H 2 0 in DMF (2.0 M) and shaken at room temperature overnight. The resins were 25 filtered and washed with DMF (x 3), DMF / MeOH (1:1, x 3), DMF (x 3), DMF / MeOH (1:1, x 3) and DCM (x 3). Cyclisation to the benzimidazole Resin bound substrate was washed with THF (x3). p-toluenesulfonic acid monohydrate 30 (catalytic) in trimethyl orthoformate and added to each of the resins. After shaking overnight the resins were drained and washed with THF (x3), MeOH (x3) and DCM (x3).

WO 2007/070947 PCT/AU2006/001939 28 Cyclisation to the benzimidazolone Resin bound substrate was washed with DCM (x3). 1,1-carbonyldiimidazole (0.1M) in DCM and added to each of the resins. After shaking overnight the resins were drained 5 and washed with DCM (x3), MeOH (x3) and DCM (x3). Cyclisation to the thiobenzimidazoleone Resin bound substrate was washed with THF (x3). 1,1-thiocarbonyldiimidazole (0.5M) in THF and added to each of the resins. After shaking overnight the resins were drained and 10 washed with THF (x3), MeOH (x3) and DCM (x3). Cyclisation to the iminobenzimidazoleone Resin bound substrate was washed with DCM (x3). A 0.5M solution of cyanogen bromide was added to each of the resins. After shaking overnight the resins were drained 15 and washed with DCM (x3), MeOH (x3) and DCM (x3). At this point the (benzimidazolone and thiobenzimidazole) resins were treated with a sodium methoxide 'in THF/MeOH solution (0.04M) to remove any 3-position carbamates/thiocarbamnates which may have formed. The resins were then drained and 20 washed with THF (x3), MeOH (x3), THF (x3) and DCM (x3). TG29 Urea Formation 25 Resin bound substrate was drained, washed with dry DMF (x 3) and treated with a solution of an isocyanate in dry DMF (0.15 M). The resin was shaken at room temperature overnight, drained and washed with DMF (x 3) and DCM (x 3).

WO 2007/070947 PCT/AU2006/001939 29 Thiourea Formation Resin bound substrate was drained, washed with dry DMF (x 3) and treated with a solution of an isothiocyanate in dry DMF (0.15 M). The resin was shaken at room temperature overnight, drained and washed with DMF (x 3) and DCM (x 3). 5 Examples of the kind of molecules synthesised are shown below. ACL00016124 has been shown to have an MIC of 1 ptg/mL against S. Aureus in the absence of serum. ACL00016116 has shown MIC's of 4pg/mL and 16 gg/mL against S. Aureus in the 10 absence and presence (5% horse serum) of serum, respectively. Finally, ACL00016105 has demonstrated MIC values from 2-4 pg/mL, against S. Aureus, S. Aureus MRSA, E. Faecium, E. Faecium VanB and E. Faecalis in the absence of serum. Biological Test Methods 15 Antibacterial testing was undertaken at a number of contract research organizations, and methods and procedures for the culture and testing of antibacterials are well documented in the scientific and technical literature. The following general procedures are provided as examples of the methods applied. 20 Testing was conducted to determine the in vitro antimicrobial activity of a series of compounds synthesised by Alchemia Pty Ltd. The antimicrobial activity of each compound was determined at a single concentration (128 ig/mL) in Mueller Hinton (MH) broth against the ATCC type strain of Staphylococcus aureus. Compounds that demonstrate activity at this level were then subjected to MIC determination in S. aureus 25 in MH broth in the absence of serum and in the presence of 5% heat inactivated horse serum. Compounds showing activity at concentrations up to 32-64 4g/mL in the presence/absence of serum were then tested for MIC activity against a standard set of 5 microorganisms comprising of ATCC type strains of MRSA, Enterococcus faecalis, Enterococcus faecium, VRE and Escherichia coli. CLSI (formerly NCCLS) microbroth 30 dilution technique was used.

WO 2007/070947 PCT/AU2006/001939 30 Procedures Test solution preparation Each compound is initially dissolved in 100 P 1 L of DMSO. Each solution is then diluted 5 further in 0.9mL of sterile MH broth to give a total volume of lmL (1000 pg/mL) This stock solution is then further diluted in MH broth to give a test solution with final concentration of 128 gg/mL using the following formula: 0.5 ml stock in 3.4 ml MH broth The test solutions are prepared on the same day as initial testing is performed. Remaining 10 stock and test solutions are then stored in labelled containers at -20oC. Test organisms The same series of organisms were tested for all compounds. These include ATCC strains: 15 Staphylococcus aureus ATCC 25923 (fully susceptible) Staphylococcus aureus (MRSA) ATCC 33591 Enterococcusfaecalis ATCC 29212 Enterococcusfaecium ATCC 35667 Escherichia coli ATCC 25922 20 Enterococcusfaecalis ATCC 51299 (VRE) Each test organism was subcultured from the -70oC deep freezer onto horse blood agar. The plates were streaked to obtain isolated colonies and incubated at 35 0 C in non-CO 2 incubator for 24 hours. A second subculture was carried out onto horse blood agar. For 25 each test organism, 1-2 colonies were selected from an 18-24 hour culture and inoculated into 2ml sterile MHII broth. The turbidity was adjusted to 0.5 McFarland standard. A 1:10 dilution in MH broth (200pL in 2ml MH) of the 0.5 McFarland control was prepared. 5pL of this diluted solution was used to inoculate the trays. MICs to vancomycin for each test organism Were determined in a single series of testing 30 as a means of confirming the test organisms were reacting within defined. MIC parameters.

WO 2007/070947 PCT/AU2006/001939 31 Activity against S.aureus 100 p1L of test solution was added to each well. The final row on each tray had sterile MH broth only added (positive control). 5 pL of test organism solution was added to each 5 well including the final row. The final well on each row had no organism solution added (negative control). The plate was then sealed and incubated at 35oC in a non-CO 2 incubator for 18-24 hours. The plates were examined for growth after the incubation time. MIC against S.aureus 10 Each compound that showed activity against S aureus (inhibition of growth in the well) was tested further to determine the actual MIC. 100pL of sterile MH broth was added in columns 2-12. 200 pL of test solution was added in column 1. 100 [tL was transferred in column 2 giving a 2 dilution. 100pL from column 2 was then transferred to column 3 (% dilution). This dilution was carried on until column 12. A second tray containing the 15 same test solution was inoculated in a similar manner using sterile MH broth with 5% heat inactivated horse serum. 5pL of organism solution was then added to each well. The plates were then sealed and incubated at 35oC in a non-CO 2 incubator for 18-24 hours. The plates were examined for growth after the incubation time. 20 MIC levels against 5 organisms Each compound that showed activity at MIC level at 32 or less in sterile MH broth and at MIC level of 64 or less in the presence of serum was tested to determine full MIC against 5 microorganisms. The trays were prepared in a similar way as mentioned above and incubated at 35oC in a non-CO 2 incubator for 18-24 hours. The plates were examined for 25 growth after the incubation time. After 18-24 hour incubation 5pL from each well was then inoculated onto horse blood agar and incubated for 18-24 hours at 35 0 C in a non-CO 2 incubator. Plate examination WO 2007/070947 PCT/AU2006/001939 32 If the test organism is sensitive to the compound in the broth the growth will be inhibited. Similarly, if the organism grows on the antibiotic containing medium then it is resistant to this particular antibiotic. The organisms were scored as follows: 5 "No Growth"= Sensitive (S) "Growth" = Resistant (R) "Scant growth"= SG All the results were recorded electronically on spreadsheets. 10 HPLC separation All compounds were separated on a Zorbax C18 (4.6 x 50mm) column. The liquid phase used was H 2 0 - Acetonitrile in the gradients described below. 5% acetonitrile from 0-1 min then gradient to 100% acetonitrile at 7min and hold until 15 12min for TG 23, 24, 27 and 29. 5% acetonitrile from 0-1 min then gradient to 30% acetonitrile at 3min, gradient to 60% acetonitrile at 11min and gradient to 100% acetonitrile at 12min and hold until 15min for TG 25 5% acetonitrile from 0-1 min then gradient to 100% H20 at 7min and hold until 12min 20 for TG 26 compounds apart from AL00016098 and AL00016114 which used 5% acetonitrile from 0-1 min then gradient to 40% acetonitrile at 3min, gradient to 70% acetonitrile at 1 1min and gradient to 100% acetonitrile at 12min and hold until 15min. Key to Building Blocks for Tables 1 and 2 25 Table 1: Compounds of formula (1) RT: retention time/minutes M+H: mass ion +1 Table 2: Biological activity of compounds of formula (1) 30 "+ +" : MIC (pg/mL): MIC <16 WO 2007/070947 PCT/AU2006/001939 33 "+": MIC ( 1 Lg/mL): 64> MIC >16 "-" MIC (pig/mL): MIC > 64 Blank: not determined WO 2007/070947 PCT/AU2006/001939 34 Table 1: Compounds of formula (1) 1 X1 X3 X9 X10 5.27 564 2 X1 X8 X9 X10 5.23 552 3 Xl X3 X9 X22 4.78 550 4 X1 X7 X9 X12 4.18 595 5 X1 X8 X9 X16 6.04 540 6 X1 X7 X9 X16 5.93 540 7 X2 X7 X9 X16 6.29 586 8 X1 X7 X81 X16 6.23 554 9 X1 X6 X9 X10 5.26 586 10 X2 X7 X9 XO10 5.22 598 11 X1 X7 X81 X10 5.43 566 12 X1 X6 X9 X11i 5.7 620 13 X1 X8 X9 X11 5.32 586 14 X1 X7 X9 X11i 5.38 586 15 X2 X7 X9 X11ii 5.58 632 16 X1 X7 X81 Xli 5.63 600 17 X1 X6 X9 X12 4.27 629 18 Xl X8 X9 X12 4.12 595 19 X2 X7 X9 X12 4.37 641 20 X1 X7 X81 X12 4.33 609 21 X1 X6 X9 X13 4.38 629 22 Xl X8 X9 X13 4.18 595 23 X1 X7 X9 X13 4.27 595 24 X2 X7 X9 X13 4.28 641 WO 2007/070947 PCT/AU2006/001939 35 25 X1 X7 X81 X13 4.32 609 26 X1 X6 X9 X17 4.78 631 27 X1 X8 X9 X17 4.72 597 28 X1 X7 X9 X17 4.68 597 29 X2 X7 X9 X17 5.12 643 30 X1 X7 X81 X17 4.93 611 31 X1 X6 X9 X14 5.77 560 32 X1 X8 X9 X14 5.53 526 33 Xl X7 X9 X14 5.58 526 34 X2 X7 X9 X14 5.79 572 35 X1 X7 X81 X14 5.84 540 36 X1 X8 X9 X15 5.18+4.68 526 37 Xl X7 X9 X15 4.71+5.23 526 38 X1 X7 X81 X15 5.27 540 39 Xl X6 X9 X19 5.18 570 40 X1 X8 X9 X19 5.02 536 41 Xl X7 X9 X19 4.98 536 42 X2 X7 X9 X19 5.17 582 43 X1 X7 X81 X19 5.23 550 44 X1 X6 X9 X18 5.32 602 45 X1 X8 X9 X18 5.13 568 46 Xl X7 X9 X18 5.12 568 47 X2 X7 X9 X18 5.33 614 48 Xl X7 X81 X18 .5.37 582 49 X1 X3 X9 X21 4.82 584 50 X1 X3 X9 X23 5.27 524 51 X1 X3 X9 X24 4.63 567 52 X1 X3 X9 X25 5.22 600 53 X1 X7 X9 X21 4.68 571 54 X1 X7 X9 X22 4.42 537 WO 2007/070947 PCT/AU2006/001939 36 55 X1 X7 X9 X23 4.93 511 56 X1 X7 X9 X24 4.67 554 57 X1 X7 X9 X25 5.28 587 58 X1 X3 X20 X21 5.27 675 59 X1 X3 X20 X22 5.08 641 60 X1 X3 X20 X23 5.72 615 61 X1 X3 X20 X24 5.64 658 62 X1 X3 X20 X25 5.42 691 63 X1 X7 X20 X21 5.14 662 64 X1 X7 X20 X22 4.87 628 65 X1 X7 X20 X23 5.43 602 66 X1 X7 X20 X24 5.37 645 67 X1 X7 X20 X25 5.38 678 68 X1 X3 X20 X16 6.18 643 69 X1 X3 X20 XIO 5.43 655 70 X1 X3 X20 X12 4.67 698 71 X1 X3 X20 X12 4.88 698 72 X1 X3 X20 X13 4.52 698 73 Xl X3 X20 X17 5.6 700 74 X1 X3 X20 X17 6.18 700 75 X1 X3 X20 X17 5.58 700 76 X1 X7 X20 X16 5.33 630 77 X1 X7 X20 X10 4.47 642 78 X1 X7 X20 X12 4.68 685 79 X1 X7 X20 X12 4.47 685 80 X1 X7 X20 X13 5.53 685 81 X1 X7 X20 X17 1 687 82 X1 X3 X9 X16 6.04 552 83 X1 X4 X9 X16 5.72 518 84 X1 X5 X9 X16 5.78 518 WO 2007/070947 PCT/AU2006/001939 37 85 X1 X77 X9 X16 5.78 534. 86 X1 X74 X9 X16 5.88 518 87 Xl X75 X9 X16 5.99 534 88 X1 X76 X9 X16 5.97 534 89 X1 X78 X9 X16 4.47 373 90 X1 X5 X9 XIO 4.97 530 91 X1 X77 X9 XIO 5.13 546 92 Xl X74 X9 X10 5.08 530 93 Xl X75 X9 X10 5.18 546 94 X1 X78 X9 XIO 3.82 385 95 X1 X5 X9 X12 4.42 573 96 X1 X74 X9 X12 4.47 573 97 X1 X75 X9 X12 4.53 589 98 X1 X76 X9 X12 4.47 589 99 X1 X78 X9 X12 3.47 428 100 Xl X3 X9 X13 4.38 607 101 Xl X4 X9 X13 4.22 573 102 X1 X5 X9 X13 4.28 573 103 Xl X77 X9 X13 4.27 589 104 X1 X74 X9 X13 4.33 573 105 X1 X76 X9 X13 4.43 589 106 X1 X78 X9 X13 3.22 428 107 Xl X3 X9 X17 5.33 609 108 X1 X4 X9 X17 5.07 575 109 X1 X5 X9 X17 4.97 575 110 Xl X77 X9 X17 5.12 591 111 Xl X74 X9 X17 5.07 575 112 Xl X4 X9 X15 5.37 504 113 Xl X5 X9 X15 5.43 504 114 Xl X77 X9 X15 5.48 520 WO 2007/070947 PCT/AU2006/001939 38 115 X1 X74 X9 X15 5.54 504 116 X1 X75 X9 X15 5.57 520 117 X1 X76 X9 X15 5.69 520 118 X1 X78 X9 X15 4.18 359 119 X1 X3 X9 X19 5.07 548 120 Xl X5 X9 X19 4.88 514 121 X1 X77 X9 X19 4.87 530 122 X1 X74 X9 X19 4.92 514 123 X1 X75 X9 X19 5.03 530 124 Xl X76 X9 X19 5.13 530 125 Xl X78 X9 X19 3.68 369 126 X1 X3 X9 X18 5.23 580 127 X1 X4 X9 X18 5.08 546 128 X1 X5 X9 X18 5.02 546 129 X1 X77 X9 X18 5.13 562 130 X1 X74 X9 X18 5.17 546 131 X1 X75 X9 X18 5.13 562 132 X1 X78 X9 X18 3.87 401 133 XI X3 X9 X80 5.54 629 134 X1 X4 X9. X80 5.23 595 135 X1 X5 X9 X80 5.33 595 136 XI X77 X9 X80 5.27 611 137 X1 X74 X9 X80 5.33 595 138 X1 X75 X9 X80 5.37 611 139 X1 X76 X9 X80 5.48 611 140 X1 X78 X9 X80 4.22 450 141 X1 X3 X9 X79 5.33 544 142 X1 X4 X9 X79 5.02 510 143 X1 X5 X9 X79 5.13 510 144 X1 X77 X9 X79 5.07 526 WO 2007/070947 PCT/AU2006/001939 39 145 Xl X74 X9 X79 5.1 510 146 X1 X75 X9 X79 5.17 526 147 X1 X76 X9 X79 5.33 526 148 X1 X78 X9 X79 3.82 365 149 X1 X65 X9 X1O 5.01 528 150 X1 X67 X9 X1O 5 544 151 X1 X63 X9 XO10 4.17 527 152 X1 X61 X9 X10 4.87 512 153 Xl X66 X9 XO10 5.21 562 154 X1 X68 X9 X10io 5.39 578 155 X1 X64 X9 X10 4.67 561 156 X1 X62 X9 X10 5.28 546 157 X1 X65 X9 X12 4.18 571 158 X1 X67 X9 X12 4.17 587 159 X1 X63 X9 X12 3.53 570 160 X1 X61 X9 X12 4.12 555 161 Xl X66 X9 X12 4.34 605 162 X1 X68 X9 X12 4.43 621 163 X1 X64 X9 X12 4.07 604 164 X1 X62 X9 X12 4.33 589 165 X1 X65 X9 X16 5.63 516 166 X1 X67 X9 X16 5.84 532 167 X1 X63 X9 X16 4.63 515 168 X1 X61 X9 X16 5.68 500 169 Xl1 X66 X9 X16 6.14 550 170 X1 X68 X9 X16 6.34 566 171 X1 X64 X9 X16 5.38 549 172 X1 X62 X9 X16 6.13 534 173 X1 X65 X9 X)15 5.27 502 174 Xl X67 X9 X15 5.32 518 WO 2007/070947 PCT/AU2006/001939 40 175 X1 X63 X9 X15 4.33 501 176 Xl X61 X9 X15 5.32 486 177 X1 X66 X9 X15 5.72 536 178 X1 X68 X9 X15 5.88 552 179 X1 X64 X9 X15 5.13 535 180 Xl X62 X9 X15 5.78 520 181 X1 X65 X9 X17 4.83 573 182 Xl X67 X9 X17 4.77 589 183 - X1 X63 X9 X17 4.18 572 184 X1 X61 X9 X17 4.77 557 185 X1 X66 X9 X17 5.03 607 186 X1 X68 X9 X17 4.97 623 187 Xl X64 X9 X17 4.83 606 188 X1 X62 X9 X17 4.77 591 189 X1 X69 X9 X10 5.77 532 190 X1 X70 X9 XIO 6.77 566 191 X1 X69 X9 X12 7.77 575 192 X1 X70 X9 X12 8.77 609 193 X1 X69 X9 X16 9.77 520 194 Xl X70 X9 X16 10.77 554 195 X1 X69 X9 X15 11.77 506 196 . X1 X70 X9 X15 12.77 540 197 X1 X69 X9 X17 13.77 577 198 X1 X70 X9 X17 14.77 611 199 X1 X71 X9 X1O 15.77 502 200 XI X72 X9 XIO 16.77 536 201 X1 X71 X9 X12 17.77 545 202 X1 X72 X9 X12 18.77 579 203 X1 X71 X9 X16 19.77 490 204 Xl X72 X9 X16 20.77 524 WO 2007/070947 PCT/AU2006/001939 41 205 X1 X71 X9 X15 21.77 476 206 X1 X72 X9 X15 22.77 510 207 X1 X71 X9 X17 23.77 547 208 Xl X3 X9 X27 5.33+5.48 588 209 Xl X3 X9 X27 5.42 588 210 X1 X7 X9 X27 7.98+8.63 575 211 X1 X7 X9 X27 8.09+8.84 575 212 Xl X3 X20 X27 9.68 679 213 X1 X3 X20 X27 10.57 679 214 Xl X7 X20 X27 9.52+10.06 666 215 X1 X3 X9 X26 8.02+8.76 580 216 X1 X3 X9 X26 8.72 580 217 X1 X7 X9 X26 7.27+8.09 567 218 X1 X7 X9 X26 7.98 567 219 X1 X3 X20 X26 9.2 671 220 X1 X3 X20 X26 9.91 671 221 X1 X7 X20 X26 9.01+9.63 658 222 X1 X7 X20 X26 9.54 658 223 X1 X3 X9 X31 7.45 632 224 X1 X7 X9 X31 6.15+6.57 619 225 X1 X3 X9 X29 6.32+6.67 590 226 X1 X7 X9 X29 5.26 577 227 X1 X7 X9 X28 7.8 590 235 X1 X3 X9 X53 6.68 793 236 X1 X3 X9 X55 5.23 777 237 X1 X3 X9 X57 5.63 791 238 X1 X3 X9 X59 5.54 791 239 X1 X7 X9 X53 6.68 780 240 X1 X7 X9 X55 5.32 764 241 X1 X7 X9 X57 5.67 778 WO 2007/070947 PCT/AU2006/001939 42 242 X1 X7 X9 X59 5.78 778 243 X1 X3 X9 X33 6.23 678 244 X1 X3 X9 X35 6.23 712 245 X1 X3 X9 X37 5.03 720 246 X1 X3 X9 X41 5.57 658 247 X1 X3 X9 X43 5.39 692 248 Xl X3 X9 X45 5.52 714 249 X1 X3 X9 X51 5.53 750 250 X1 X3 X9 X47 5.27 734 251 X1 X3 X9 X49 6.29 708 252 X1 X3 X9 X34 6.53 712 253 X1 X3 X9 X36 6.49 746 254 X1 X3 X9 X38 5.28 754 255 X1 X3 X9 X42 5.82 692 256 X1 X3 X9 X44 5.83 726 257 X1 X3 X9 X46 8.04 748 258 Xl X3 X9 X52 5.74 784 259 Xl X3 X9 X48 5.74 768 260 X1 X3 X9 X50 5.67 742 261 X1 X3 X9 X50 5.78 742 262 X1 X7 X9 X33 5.93 665 263 X1 X7 X9 X35 5.88 699 264 X1 X7 X9 X37 4.77 707 265 X1 X7 X9 X41 4.83 645 * 266 Xl X7 X9 X43 5.37 679 267 X1 X7 X9 X45 5.23 701 268 X1 X7 X9 X51 5.27 737 269 X1 X7 X9 X47 4.93 721 270 X1 X7 X9 X49 6.28 695 271 X1 X7 X9 X34 6.24 699 WO 2007/070947 PCT/AU2006/001939 43 272 X1 X7 X9 X36 6.48 733 273 X1 X7 X9 X38 4.98 741 274 X1 X7 X9 X42 5.32 679 275 X1 X7 X9 X44 5.53 713 276 X1 X7 X9 X46 5.72 735 277 X1 X7 X9 X52 5.43 771 278 X1 X7 X9 X48 5.47 755 279 X1 X7 X9 X50 1 729 Table 2: Biological activity of compounds of formula (1) Compound S.Aureus S.Aureus E.Faecium E.Faecium E.Fecalis number 25923 33591 35667 51299 29212 MRSA VanB activity activity activity activity activity 7 + + - - 8 + - - - 12 + 26 + 27 + 29 ++ 30 + 50 + + + - + 62 + ++ - 69 + - - 70 + ++ + - + 71 ++ ++ ++ + + 72 ++ 73 ++ ++ ++ + ++ WO 2007/070947 PCT/AU2006/001939 44 74 + + + + 75 ++ 79 + + - - 88 + + + + + 107 ++ ++ + + + 108 + + - - 109 ++ + - - 153 + + - + 155 + + - - 156 + - + - 161 + + - - + 163 + + - - + 169 + + + + + 170 - ++ + ++ 171 + + - - 172 + + - - 177 + + + - 178 + - - - 179 + - - - 181 + ++ + + + 182 ++ ++ ++ ++ ++ 183 + - ++- 185 + ++ ++ + ++ 186 ++ + - - + 187 ++ ++ + ++ ++ 188 + + - + + 197 ++ + + + + 198 + + + + + 200 - + - - 202 + + + - WO 2007/070947 PCT/AU2006/001939 45 207 + + + + + 236 - ++ ++ + ++ 237 - ++ - ++ 238 - ++ ++ 240 ++ ++ ++ 241 ++ ++ ++ + ++ 242 ++ ++ ++ ++ 246 ++ ++ + + ++ 247 ++ ++ ++ ++ 248 ++ ++ ++ ++ ++ 249 ++ ++ ++ ++ ++ 251 ++ ++ ++ ++ ++ 252 + 253 - 254 ++ ++ . 255 ++ ++ + ++ 256 - - ++ ++ 258 ++ 259 ++ 261 ++ 262 + 263 ++ 264 ++ 265 + 266 ++ 267 ++ 268 ++ 269 ++ 270 ++ 271 ++ WO 2007/070947 PCT/AU2006/001939 46 272 ++ 273 ++ 274 ++ 275 ++ 276 + 277 + 278 ++ 279 ++ WO 2007/070947 PCT/AU2006/001939 47 Figure 1: Sidearms for Table 1. NH NH O- NH OJ- NH H SMe

CF

3 CF 3 Cl X1 X2 X3 X4 Cl-NH O-NH HNSO2 HN SO 2 H NSO

CF

3 CF3 CF 3 OH

CF

3 X5 X6 X7 X8 X9

H

2 N O H CI H NH NHN X1O Xli X12 X13 X14 X15 0_0 HN~eN 16X7H X13 X1 X15 WO 2007/070947 PCT/AU2006/001939 48 0 HNo

H

NH

2 X19 X20 X21 X22 H - HN H H X23 X24 X25

CF

3

-

OH OMe N\ N NN, N \ NH 2 N- F N, F NNN 'N \/C 3 ~ F X26 X27 X28 X29 X30 0OH 0N-Km' N CF 3 N.N NN It It CIO X31 X32X3 N .~CF 3 HN-K CF 3 N :C CF 3 N F 3 HN- / I HN-/ N N~ N CIO CI:l-J l

CI=

3 C F 3 C X34 X35 X36 X37 WO 2007/070947 PCT/AU2006/001939 49 N CF 3 N CF 3 N CF 3 N</ - N - N CF3 N- <HN-K/ X38 X39 X40 X41 N ~ CF 3 N CF 3 N '~CF 3 HN-K/ HN-K' , HN / \ N CI N - C' N X42 X43 X44 N CF 3 N CF 3 N CF HN-K'I HN-HN - i -L 'JCI X45. X46 X47 N CF 3 N CF 3 ND( CF 3 HN-K/I y HN-K/K H K/ N - / N -~- / N S -- u4k cl kU' CI X48 X49 X50 5 WO 2007/070947 PCT/AU2006/001939 50 HN-K C 3

CF

3 / \N - /\ HN - CF, 0 CI 0 N/

H

3

C(H

2

C)

1 1 -NY N

NH

2 H X51 X52 X53

CF

3 CF, CF - S 3

H

3

C(H

2

C

1 NAN NO 0 N.I N N A

NH

2

NH

2 NN C

NH

2 H '' X54 X55 -X56

CF

3 CF,

CF

3 0N \ 0

N/H

2 N 0 N\ N NIA I N N S ,,-

NH

2 HNHH

N'

I 17 7 X57 X58 X59

CF

3

H

2 N 0 N 0Cl N) N N Ci N- N H~A ,> N

-~F

3 C OCN /> />NH FC & N F 3 C, X60 X61 X62 X63 WO 2007/070947 PCT/AU2006/001939 51 Ci/ CI N N - N ~ - N

F

3 NH, F 3 >-OH 3>-OH F3 I SH NaC F 3 C 10CN F 3 C i N X64 X65 X66 X67 C y1 Cl- C , - sN NH c NH c NH c NH

F

3 C~ I,>-SH FC N 2 O "6 N FF0 ,C' N 2 F C CNH 2 6 N F3 C

F

3 F 3 C 2 2 X68 X69 X70 X71 X72 , NH 'NH NH 0ONH SNH H S NH ONH NA<N NCl S ICF3 CI 3

CF

3 0

'CF

3 X73 X74 X75 X76 X77 CI 0 0 HH I HH OMe N H NN 'N X78 X79 X80 X81 X82 5 It should be appreciated that various other changes and modifications can be made to the specification without departing from the spirit and scope of the invention.

Claims (27)

1. A method of inhibiting bacterial growth by contacting bacteria with at least one 5 monosaccharide compound of formula (1): o R1 R5 R4 R2 R3 n formula I 10 Wherein, n is 0 or 1; the ring may be of any configuration and the anomeric center may be of either the oc or 13 configuration; R1 is selected from the group consisting of hydrogen; OZ; SZ; OP0 2 (OZ)Z; SO 2 N(Z)Q; S(=O)N(Z)Q; N-Het wherein N and Het combine to form a heterocycle 15 which may be further substituted with U groups; and -N(Z)Y wherein: Y is selected from hydrogen, or the following, where G denotes the point of connection to the nitrogen atom in N(Y)Z; WO 2007/070947 PCT/AU2006/001939 53 0O O G W 0 G W GS"' W G S S oW / G P 0 *,W G/ G N OH I 5 Q is selected from hydrogen or W; the groups W are independently selected from alkyl, alkenyl, alkynyl, heteroalkyl, aryl, heteroaryl, arylalkyl or heteroarylalkyl of 1 to 20 carbon atoms which is optionally substituted, branched and/or linear. Typical substituents include but are not limited to OH, NO, NO 2 , NH 2 , N 3 , halogen, CF 3 , CHF 2 , CH 2 F, nitrile, alkoxy, aryloxy, amidine, 10 guanidiniums, carboxylic acid, carboxylic acid ester, carboxylic acid amide, aryl, cycloalkyl, heteroalkyl, heteroaryl, aminoalkyl, aminodialkyl, aminotrialkyl, aminoacyl, carbonyl, substituted or unsubstituted imine, sulfate, sulfonamide, phosphate, phosphoramide, hydrazide, hydroxamate, hydroxamic acid; the term heteroalkyl includes alkyl groups which incorporate one or more heteroatoms within the alkyl chain; 15 each occurrence of Z is independently selected from the group consisting of: hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, acyl, arylacyl, heteroarylacyl, aryl, heteroaryl, arylalkyl or heteroarylalkyl of 1 to 20 carbon atoms which is optionally Substituted, branched and/or linear. Typical substituents include but are not limited to 20 OH, NO, NO 2 , NH 2 , N 3 , halogen, CF 3 , CHF 2 , CH 2 F, nitrile, alkoxy, aryloxy, amidine, guanidiniums, carboxylic acid, carboxylic acid ester, carboxylic acid amide, aryl, cycloalkyl,'heteroalkyl, heteroaryl, aminoalkyl, aminodialkyl, aminotrialkyl, aminoacyl, carbonyl, substituted or unsubstituted imine, sulfate, sulfonamide, phosphate, WO 2007/070947 PCT/AU2006/001939 54 phosphoramide, hydrazide, hydroxamate, hydroxamic acid; the term heteroalkyl includes alkyl groups which incorporate one or more heteroatoms within the alkyl chain; or wherein each occurrence of U is independently selected from the group consisting of: 5 OH, NO, NO 2 , NH 2 , N 3 , halogen, CF 3 , CHF 2 , CH 2 F, nitrile, alkoxy, aryloxy, amidine, guanidinium, carboxylic acid, carboxylic acid ester, carboxylic acid amide, aryl, cycloalkyl, heteroalkyl, heteroaryl, aminoalkyl, aminodialkyl, aminotrialkyl, aminoacyl, carbonyl, substituted or unsubstituted imine, sulfate, sulfonamide, phosphate, phosphoramide, hydrazide, 'hydroxamate, hydroxamic acid; heteroaryloxy, aminoaryl, 10 aminoheteroaryl, thioalkyl, thioaryl, thioheteroaryl, alkyl, alkenyl, alkynyl, acyl, arylacyl, heteroarylacyl; of 1 to 20 carbon atoms which is optionally substituted, branched and/or linear; and the groups R2, R3, R4 and R5 are independently selected from OZ or N-Het wherein N 15 and Het combine to form a heterocycle which may be further substituted with U groups; or N(Z)Y or OP0 2 (OZ)Z, wherein the groups Z and Y are as defined above.

2. The method according to claim 1 wherein the compound is selected from the group consisting of the gluco- or galacto- or allo- configuration. 20

3. The method according to any one of claim 1 or 2 wherein any one of R1-R5 is N-Het.

4. The method according to any one of claims 1-3 wherein the heterocycle is a monocyclic or bicyclic ring of 4 to 10 membered ring structure. 25

5. The method according to any one of claims 1-4 wherein any one of R2 and R4 is N Het, wherein the heterocycle is a monocyclic or bicyclic ring of 4 to 10 membered ring structure WO 2007/070947 PCT/AU2006/001939 55

6. The method according to any one of claims 1-5 wherein the heterocyclic ring includes triazoles, benzimidazoles, benzimidazolothione, benzimidazolone, imidazole, hydanthione, thiohydanthione and purine. 5

7. A compound of formula (1) wherein any one of R1-R5 is N-Het.

8. The compound according to claim 7 wherein the heterocycle is a monocyclic or bicyclic ring of 4 to 10 membered ring structure. 10

9. The compound according to claim 8 wherein any one of R2 and R4 is N-Het, wherein the heterocycle is a monocyclic or bicyclic ring of 4 to 10 membered ring structure.

10. The compound according to any one of claims 7 to 9 wherein the compound is selected from the group consisting of the gluco- or galacto- or allo- configuration. 15

11. The compound according to any one of claims 7-10 wherein the heterocyclic ring includes triazoles, benzimidazoles, benzimidazolothione, benzimidazolone, imidazole, hydanthione, thiohydanthione and purine. 20

12. The compound according to any one of claims 7-11 wherein the heterocyclic ring may be further substituted with U groups; wherein each occurrence of U is independently selected from the group consisting of: OH, NO, NO 2 , NH 2 , N 3 , halogen, CF 3 , CHF 2 , CH 2 F, nitrile, alkoxy, aryloxy, amidine, guanidinium, carboxylic acid, carboxylic acid ester, carboxylic acid amide, 'aryl, cycloalkyl, heteroalkyl, heteroaryl, aminoalkyl, 25 aminodialkyl, aminotrialkyl, aminoacyl, carbonyl, substituted or unsubstituted imine, sulfate, sulfonamide, phosphate, phosphoramide, hydrazide, hydroxamate, hydroxamic acid; heteroaryloxy, aminoaryl, aminoheteroaryl, thioalkyl, thioaryl, thioheteroaryl, alkyl, alkenyl, alkynyl, acyl, arylacyl, heteroarylacyl; of 1 to 20 carbon atoms which is optionally substituted, branched and/or linear. 30 WO 2007/070947 PCT/AU2006/001939 56

13. The compound according to claim 12 wherein the heterocyclic ring may be further substituted with U groups selected from the group consisting of substituted alkyl, aryl, carboxyl and amino. 5

14. The compound according to any one of claims 12 or 13 wherein the U group is selected from the group consisting of OH, NO, NO 2 , NH 2 , N 3 , halogen, CF 3 , CHF 2 , CH 2 F, nitrile, alkoxy, aryloxy, amidine, guanidinium, carboxylic acid, carboxylic acid ester, carboxylic acid amide, aryl, cycloalkyl, heteroalkyl, heteroaryl, primary, secondary or tertiary amines, aminoacyl, carbonyl and substituted or unsubstituted imine. 10

15. The method of any one of claims 1-6 wherein in each occurrence Z is independently selected from the group consisting of: hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, acyl, arylacyl, heteroarylacyl, aryl, heteroaryl, arylalkyl or heteroarylalkyl of 1 to 20 carbon atoms which is optionally substituted, branched and/or linear. 15

16. The method of any one of claims 1-6 wherein the substituents include OH, NO, NO 2 , NH2, N 3 , halogen, CF 3 , CHF 2 , CH 2 F, nitrile, alkoxy, aryloxy, amidine, guanidiniums, carboxylic acid, carboxylic acid ester, carboxylic acid amide, aryl, cycloalkyl, heteroalkyl, heteroaryl, aminoalkyl, aminodialkyl, aminotrialkyl, aminoacyl, carbonyl, 20 substituted or unsubstituted imine, sulfate, sulfonamide, phosphate, phosphoramide, hydrazide, hydroxamate, hydroxamic acid; the term heteroalkyl includes alkyl groups which incorporate one or more heteroatoms within the alkyl chain.

17. The compound of any one of claims 7-14 selected from the following: CF 3 CF 3 N FN O N N OO H NHON OH HOS NH NH 0225 CF3 C F C F 3 25 CF 3 CI CF 3 CI CF 3 WO 2007/070947 PCT/AU2006/001939 57

18. A pharmaceutical composition comprising a compound of formula (1) described herein, or tautomers, esters, solvates, or pharmaceutically acceptable salts thereof, and a pharmaceutically acceptable carrier. 5

19. The method of any one of claims 1-6 wherein the bacterial is Gram-positive bacteria.

20. The method of any one of claims 1-6 wherein the bacterial may be Gram-positive or Gram-negative bacteria comprising an E-coli bacteria, a Staphylococci Bacteria such as Staphylococcus aureus, or other bacteria such as Micrococcus luteus, Staphylococcus 10 aureus Staphylococcus aureus MRSA, Enterococcus faecalis, Enterococcus faecalis Vancomycin resistant and Streptococcus pyogenes.

21. The method of any one of claims 1-6, 15, 16 and 19-20 comprising administering an effective amount of a compound of formula (1), to a subject in need of such treatment. 15

22. An antibacterial composition comprising at least one compound as described above.

23. A pharmaceutical composition comprising at least one compound of formula (1) when administered together with one or more drugs, including antibacterial agents such as antibiotics, for the treatment of bacterial infections. 20

24. A compound of formula (1) when used for the treatment of a disease.

25. A pharmaceutical composition comprising a compound of formula (1) when used for the treatment of a disease. 25

26. A compound as hereinbefore described according to Table 1.

27. A compound of formula (1) wherein R1 is silyloxy and R2, R3, R4 and R5 are as defined in claim 1. 30